tj-m2010-2

TJ-M2010-2 is a novel small molecule inhibitor designed to specifically target and inhibit MyD88 homodimerization, thereby blocking the Toll-like receptor (TLR)/MyD88 signaling pathway. This drug was developed as a potential therapeutic for acute and chronic renal ischemia-reperfusion injury (IRI), with promising preclinical results showing protection against kidney damage, reduced inflammation, and attenuation of renal fibrosis by suppressing epithelial-mesenchymal transition (EMT)[1]. The drug demonstrates robust anti-inflammatory and anti-apoptotic effects in vivo and in vitro, significantly reducing markers of kidney injury (serum creatinine, blood urea nitrogen), inflammatory cytokines (IL-1β, IL-6, TNF-α), NF-κB activation, and reactive oxygen species (ROS) production, while increasing anti-inflammatory IL-10 levels[1]. TJ-M2010-2 also inhibits dendritic cell maturation and subsequent T-cell proliferation, indicating potential immunomodulatory effects beyond direct MyD88 inhibition[1].